Veloxis Pharmaceuticals, INC
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersCary, NC
US patents34
SAM.gov UEIYJQMS7XCLTM7
CAGE code79YG9
Incorporated inDE
LEI549300YD7MO7TUE8GX79
Brands
Briefcase
Press ReleaseThis company sells these brands.
- new therapies
- programs
- transplant healthcare providers
- global network
- Asahi Kasei
- transplant medicine
Named on the company’s own website, read JUL 29, 2026
CareersCareers page — seen SEP 8, 2026
Supplier designations
For Profit Organization
Self-certified by the company in its SAM.gov registration
Patents
34 US patents granted 2012–2025, 10 of them in the five years to SEP 2025.
Pharmaceuticals 34
- Stabilized tacrolimus compositionUS 12,403,095 · granted SEP 2, 2025
- Tacrolimus for improved treatment of transplant patientsUS 12,083,103 · granted SEP 10, 2024
- Regimen for suppressing organ rejectionUS 11,957,666 · granted APR 16, 2024
- Stabilized tacrolimus compositionUS 11,419,823 · granted AUG 23, 2022
- Regimen for suppressing organ rejectionUS 11,141,408 · granted OCT 12, 2021
Newest 5 shown · Granted to Veloxis Pharmaceuticals, INC. · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Veloxis Pharmaceuticals, INC | Cary | NC | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.